Table 3.
Extrarenal manifestations at baseline and during follow-up
| Extrarenal manifestations | At baseline, pt no (%) | Pt no with baseline symptom resolution; Median months to symptom resolution (range) | New episodes, pt no (%) |
|---|---|---|---|
| General symptoms | 18 (54) | 18/18; 1 (1-2) | 8 (24) |
| Rash | 15 (45) | 15/15; 2 (1-15) | 9 (27) |
| Oral ulcers | 4 (12) | 4/4; 1.5 (1-5) | 5 (15) |
| Arthralgias/arthritis | 13 (39) | 12/13; 1 (1-5) | 10 (30) |
| Alopecia | 4 (12) | 4/4; 1.5 (1-2) | 2 (6) |
| Myalgias | 4 (12) | 4/4; 1 (1-2) | 2 (6) |
| Serositis | 8 (24) | 8/8; 1 (1-8) | 2 (6) |
| Pneumonitis | 2 (6) | 2/2; 1.5 (1-2) | 1 (3) |
| Thrombosis | 2 (9) [1 PE, 2 DVTs] | 2/2 | 0 |
| CNS | 2 (6) [brain infarcts] | 1 both pts | 1 (3) [seizures] |
| Myositis | 0 | 1 (3) | |
| Hepatosplenomegaly | 5 (15) | 5/5 | 1 (3) |
| Anemia (Hb < 12 g/dl for female and < 13.5 g/dl for male) | 15 (45) | 10/15; 4 (1-18) | 5 (15) |
| Hemolytic anemia | 8 (24) | 2 (6) | |
| Aplastic anemia | 1 (3) | 1 (3) | |
| Leucopenia (<3.500/mm3) | 13 (39) | 11/13; 1 (1-14) | 8 (24) |
| Thrombocytopenia (<100.000/mm3) | 0 | 0 | |
| Increased liver enzymes | 5 (15) | 5/5; 1 (1-2) | 2 (6) |
PE, pulmonary embolism; DVT, deep vein thrombosis; CNS, central nervous system; Hb, hemoglobin.